Sayfa 1 itibaren 43 Sonuçlar
This invention pertains to sesquiterpene lactones and sesquiterpene lactone-containing plant extracts and preparations for pharmaceutical uses, particularly the use of sesquiterpene lactones for the treatment of severe inflammatory disorders, for example, sepsis, septic shock, or septicemia.
A large
The present invention relates to anti-inflammatory lactones.
In one aspect the present invention provides a compound of formula
##STR00002## such as a compound of formula
##STR00003## wherein R is hydroxy or amino.
A compound of formula I includes a compound of formula I'.
Preferably in a compound
FIELD OF THE INVENTION
The present inventions are generally in the fields of pharmaceutically active lactones, their pharmaceutical formulations, and method of use thereof, and methods for the synthetic preparation of chemically functionalized lactones useful therefor as anticancer, antiinfective
The present inventions are generally in the fields of pharmaceutically active lactones, their pharmaceutical formulations, and method of use thereof, and methods for the synthetic preparation of chemically functionalized lactones useful therefor as anticancer, antiinfective and anti-inflammatory
BACKGROUND OF THE INVENTION
Concurrently filed U.S. patent application Ser. No. 519,852, now U.S. Pat. No. 4,447,445 relates to the discovery of the analgesic and anti-inflammatory properties of manoalide.
The present invention relates to synthetic analogs of manoalide which have been shown to have
BACKGROUND OF THE INVENTION
The standard synthesis for pyrazoles involves the reaction of a .beta..epsilon..tau..alpha.-dicarbonyl compound with a hydrazine under mild conditions. See A. R. Katritzky in "The Principles of Heterocyclic Chemistry", Academic Press, New York (1968) at page 139. When the
FIELD OF THE INVENTION
The present invention relates generally to a composition exhibiting synergistic inhibition of the expression and/or activity of inducible cyclooxygenase-2 (COX-2). More particularly, the composition comprises a combination of a diterpene triepoxide lactone species and a
FIELD OF THE INVENTION
The present invention relates generally to a composition exhibiting synergistic inhibition of the expression and/or activity of inducible cyclooxygenase-2 (COX-2). More particularly, the composition comprises, as a first component, a diterpene triepoxide lactone species and,
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to compositions that can be used to treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and/or NF.kappa.B, to methods of modulating inflammation, including in
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to synergistic compositions that treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and to methods of modulating inflammation in cells. More specifically,
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to synergistic compositions that treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and to methods of modulating inflammation in cells. More specifically,
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to compositions that can be used to treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and/or NF.kappa.B, to methods of modulating inflammation, including in
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to compositions that can be used to treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and/or NF.kappa.B, to methods of modulating inflammation, including in
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to compositions that can be used to treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and/or NF.kappa.B, to methods of modulating inflammation, including in
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to synergistic compositions that treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and to methods of modulating inflammation in cells. More specifically,